Welcome to the all-new Vetlearn

  • Exciting News Coming to Vetlearn in August 2014!
    Coming soon you'll be able to access...
  • Nearly 5,000 Compendium and Veterinary
    Technician
    articles
  • Thousands of industry Conference Proceedings
  • All-new articles (CE and other topics) for the
    entire healthcare team
  • Over 500 hours of interactive CE Videos
  • An engaging new community for asking
    questions, making connections and more!

To access Vetlearn, you must first sign in or register.

registernow

  • Registration for new subscribers will open in August 2014!
  • Watch for additional exciting news coming soon!
Become a Member

Reference Desk June 2012

Merial Launches PUREVAX® Recombinant FeLV Vaccine

    New molecular technology provides improved potency

    DULUTH, Georgia, June 22, 2012—Merial’s PUREVAX® Recombinant FeLV, the newest addition to its line of non-adjuvanted feline vaccines, is now available. Delivered subcutaneously by needle injection, PUREVAX Recombinant FeLV features improved potency, providing excellent protection with a lower antigen concentration than PUREVAX Recombinant Leukemia Vaccine.

    Feline leukemia virus (FeLV) can lead to contagious, incurable and lethal disease.  FeLV causes cancer in about 20% of infected cats  and contributes to the development of other infectious diseases and anemia by suppressing the immune system and function of bone marrow. The American Association of Feline Practitioners (AAFP) recommends FeLV vaccination for all kittens,  and an annual booster inoculation is recommended for cats considered to be at risk of exposure which include those not housed strictly indoors.

    “PUREVAX Recombinant FeLV offers the convenience of subcutaneous delivery with the efficacy and safety you would expect from a non-adjuvanted recombinant vaccine,” said Robert Menardi, DVM, marketing director for Pet Vaccines, Merial. “Non-adjuvanted vaccines may help reduce the potential risks associated with adjuvants, which include injection site reaction, injection site granuloma or chronic inflammation.”

    About PUREVAX
    Merial developed PUREVAX Recombinant FeLV in response to customer desire for a safe, efficacious, non-adjuvanted product with convenient route of administration. PUREVAX Recombinant FeLV uses recombinant canarypox-vectored vaccine technology, which stimulates FeLV-specific cell-mediated immunity and is proven effective in the face of severe challenge.

    PUREVAX Recombinant FeLV is recommended for the vaccination of healthy cats 8 weeks or older as an aid in the prevention of disease due to feline leukemia virus. For primary vaccination, cats should receive two 1-ml dose vaccinations, three weeks apart. Annual booster injections are recommended in cats considered to be at risk of exposure. Diagnostic testing for FeLV prior to vaccination also is recommended.

    About Merial
    Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs approximately 5,600 people and operates in more than 150 countries worldwide. Its 2011 sales were more than $2.8 billion. Merial is a Sanofi company. For more information, visit www.merial.com.

    Source: Merial

    didyouknow

    Did you know... For years, biologists have been amazed by the power of gecko feet, which let these 5-ounce lizards produce an adhesive force roughly equivalent to carrying nine pounds up a wall without slipping.Read More

    These Care Guides are written to help your clients understand common conditions. They are formatted to print and give to your clients for their information.

    Stay on top of all our latest content — sign up for the Vetlearn newsletters.
    • More
    Subscribe